Mr Andy Nordin was born in Adelaide, which is where he also completed his undergraduate studies in medicine. After working as a General Practitioner in Somerset, Andy came to the UK where he completed his speciality training in Obstetrics & Gynaecology in Taunton, Basingstoke, London and Newcastle.
His specialist interests cover all aspects of gynaecological malignancy and ovarian cancer, but also includes vulval disorders. He is able to offer surgical interventions for these pathologies.
Andy served as national lead for gynaecology for the Cancer Services Collaborative / NHS Improvement for 10 years, developing his interest in clinical service improvement and redesign.
From 2004 until 2014 he chaired the UK's national forum of gynae-oncology clinical leaders (The NSSG Leads Group). From 2007 until 2015 he chaired the National Cancer Intelligence Network (NCIN) Gynaecology Clinical Reference Group. Following this, from 2013 until 2016 Andy chaired the British Gynaecological Cancer Society (BGCS) Commissioning Group. He was elected President of the BGCS for a three year term from 2016 to 2019. He is a clinical advisor for Ovacome, Target Ovarian Cancer, Jo's Cervical Cancer Trust, The Eve Appeal and MacMillan Cancer Relief.
Andy is a member or the uterine cancer trials committee of the EORTC Gynecological Cancer Group, and he sits on the trial management group and steering committees of a number of national clinical trials and audits, including the RT3 VIN vulval dysplasia trial. Andy’s research interests also include quality of life questionnaires and cancer survivorship patient reported outcome measures (PROMS), and he has been an active member of the EORTC Quality of Life Group for more than 10 years. Andy jointly leads the UKGOSOC surgical outcomes and complications audit project, and is the English representative on the ovarian cancer clinical committee for the International Cancer Benchmarking Partnership.